Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Combined With Anlotinib and Bemarituzumab in Advanced RCC
NCT07470840Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Feb 2027
- Primary completion
- Feb 2029
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, bemarituzumab in renal cell carcinoma (RCC), sponsored by Fujian Medical University Cancer Hospital. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
anlotinibbemarituzumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07470840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07470840.